Format

Send to

Choose Destination
See comment in PubMed Commons below
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(9):1707-9.

[Efficacy and toxicity of trastuzumab combined vinorelbine in 21 patients with HER2 overexpressing metastatic breast cancer].

[Article in Chinese]

Author information

  • 1State Key Laboratory of Oncology in South China/Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China. zhounn@mail.sysu.edu.cn

Abstract

OBJECTIVE:

To evaluate the efficacy and toxicity in patients with HER2 overexpressing metastatic breast cancer.

METHODS:

Twenty-one patients with HER2 overexpressing metastatic breast cancer entered into the study. Trastuzumab (8 mg/kg day 1, then 6 mg/kg every 21 days or 4 mg/kg, then 2 mg/kg every week) and vinorelbine (25 mg/m(2)) was given on days 1 and 8 every 21 days.

RESULTS:

Overall 56 cycles were given to the 21 patients enrolled into the study (mean 2, range 1-6). All can be evaluated. The response rate was 33.33% (7/21), one patient achieved complete response (CR), six patients achieved partial response (PR), four patients achieved stable disease (SD), ten patients achieved progressive disease (PD)]. The median time to progression was 3.5 months. One year overall survival was 33%. The major toxicity was myelosuppression and peripheral neuritis. A few patients were observed with fever and lower grade cardiac failure.

CONCLUSION:

The combination of trastuzumab and vinorelbine is an effective and well tolerated therapy in patients with pretreated metastatic breast cancer.

PMID:
18819904
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for SOUTHERN MEDICAL UNIVERSITY
    Loading ...
    Support Center